



**84<sup>TH</sup> ANNUAL MEETING OF THE AMERICAN THYROID ASSOCIATION**  
**October 29 – November 2, 2014**  
Hotel Del Coronado, Coronado, California [www.thyroid.org](http://www.thyroid.org)

**MEETING PROGRAM** (as of 10/7/2014)  
*Information subject to change*

Wednesday, October 29, 2014
Registration Open 2:00 PM – 8 :30 PM Exhibit Hall Open 7:30 PM – 9:00 PM
<b>ATA/AACE Advanced Endocrine Neck Ultrasound Course</b> 7:00 AM – 5:00 PM Chairs: Susan Mandel and Robert Levine
<b>E. Chester Ridgway Trainee Conference</b> 7:00 AM – 5:00 PM Chairs: Andrew Gianoukakis and Stephanie Fish
<b>Welcome/Opening Remarks</b> 5:30 PM – 5:45 PM Hossein Gharib, ATA President John C. Morris, III, Secretary/COO R. Michael Tuttle, Program Co-Chair Fredric Wondisford, Program Co-Chair
<b>Opening Session: Recent Developments and Future Challenges in Thyroidology</b> 5:45 PM – 7:30 PM <i>Chairs: R. Michael Tuttle and Fredric Wondisford</i>  Basic: Peter Kopp Clinical: Douglas Ross Surgical: Herb Chen
<b>ATA Welcome Reception</b> 7:30 PM – 9:00 PM

<b>84<sup>th</sup> Annual Meeting of the ATA</b> Thursday, October 30, 2014 Registration Open 6:30 AM – 5:30 PM	
<b>Early Riser Symposium: Medullary Thyroid Cancer</b> 6:45 AM – 8:00 AM <i>Chair: Jennifer Sipos</i>  Prophylactic Thyroidectomy in MEN2: When and Why? Steven Waguespack Management of Persistent/Recurrent Disease in the Neck Jeffrey Moley Management of Persistent/Recurrent Disease in Distant Sites Manisha Shah	
<b>Plenary Lecture: Clinical, Ethical and Legal Implications of Incidental Germ Line Findings</b> <b>Discovered as Part of Sequencing Studies</b> 8:10 AM – 8:55 AM <i>Introduction: R. Michael Tuttle</i> <b>Speaker: Mark Robson</b>	
<b>Highlighted Oral Abstract Session (4 total)</b> 9:00 AM – 10:00 AM <i>Chairs: R. Michael Tuttle and Fredric Wondisford</i>  <i>Highlighted Oral Abstract 1, Autoimmunity, Clinical</i> DOUBLE VISION IS THE MOST COMMON INDICATION FOR THERAPY IN MODERATE TO SEVERE GRAVES' ORBITOPATHY BUT IT CORRELATES NEGATIVELY WITH INFLAMMATORY SIGNS AND PROPTOSIS. A SINGLE CENTER PROSPECTIVE COHORT STUDY (N=215) WITH OBJECTIVE QUANTITATION OF DIPLOPIA <b>Peter Laurberg, D.C. Berman, I.B. Pedersen, S. Andersen, A. Carlé</b>  <i>Highlighted Oral Abstract 2, Autoimmunity, Translational</i> CRYSTAL STRUCTURE OF A TSH RECEPTOR MONOCLONAL ANTIBODY PROVIDES EVIDENCE THAT A TRIMER OF THE SHED RECEPTOR A-SUBUNIT IS THE CRITICAL IMMUNOGEN IN GRAVES' DISEASE <b>Chun-Rong Chen, P. Hubbard, S.M. McLachlan, R. Murali, B. Rapoport</b>  <i>Highlighted Oral Abstract 3, Autoimmunity, Translational</i> DEVELOPMENT OF A UNIQUE MOUSE MODEL FOR GRAVES' DISEASE THAT SPONTANEOUSLY DEVELOPS PATHOGENIC TSH RECEPTOR ANTIBODIES <b>Sandra M. McLachlan, H. Aliesky, B. Banuelos, B. Rapoport</b>  <i>Highlighted Oral Abstract 4, Thyroid &amp; Development, Basic</i> DIFFERENTIATION OF HUMAN EMBRYONIC STEM (HES) CELLS INTO THYROID CELLS <b>Risheng Ma, R. Latif, T.F. Davies</b>	
Exhibit Hall Open 10:00AM – 4:30 PM Poster Review Session and Break in the Exhibit Hall 10:00 AM – 11:00 AM	
<b>Meet the Professor Workshops (5 total)</b> 11:00 AM – 12:00 PM	
Clinical  <ul style="list-style-type: none"> <li>• Thyroid Disease and Pregnancy Robin Peeters</li> <li>• Management of Persistent/Recurrent Differentiated Thyroid Cancer: When to Treat, When to Watch? Mona Sabra and Gary Clayman</li> <li>• TSH Suppression in Thyroid Cancer: Optimizing Risks vs. Benefits Irwin Klein and Anne Cappola</li> <li>• Fukushima Daiichi Accident and Thyroid Cancer Shigenobu Nagataki</li> </ul>	Basic/Translational  <ul style="list-style-type: none"> <li>• Genome Wide Analysis of Signaling Laurent Sachs</li> <li>• In Vivo Modulation of Thyroid Hormone Action by Cofactors Anthony Hollenberg</li> </ul>
<b>Lunch and Poster Review on Your Own</b> 12:00 PM – 12:55 PM	
<b>ATA Committee Meetings Luncheon</b> (for 2014 ATA Committee members) 12:00 PM – 12:55 PM	
<b>ATA Expo Theater with Bayer Healthcare/Onyx Pharmaceuticals</b> 12:00 PM – 12:55 PM NEXAVAR® (sorafenib) in Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Cancer Refractory to Radioactive Iodine Treatment: The Phase 3 DECISION Trial <i>(Open to all attendees; space limited – first come, first served)</i> <b>Speaker: Ezra Cohen, MD</b>	
<b>Sidney H. Ingbar Award Lecture: Role of Thyroid Hormones in Skeletal Development and Bone Maintenance</b> 1:00 PM – 1:45 PM <i>Introduction: Sheue-yann Cheng</i> <b>Speaker: Graham Williams</b>	

**84<sup>th</sup> Annual Meeting of the ATA**

Thursday, October 30, 2014 (continued)

**Oral Abstract Sessions 1:50 PM – 3:20 PM**

Clinical (6 total) <i>Chairs: Naifa Busaidy and Wendy Sacks</i>	Basic/Translational Research Awards (6 total) <i>Chairs: Ronald Koenig and Yun-Bo Shi</i>
<p>Oral Abstract 11, <i>Thyroid Cancer, Clinical</i> LONG-TERM MODERATE THYROID HORMONE SUPPRESSION THERAPY IS ASSOCIATED WITH IMPROVED OUTCOMES IN DIFFERENTIATED THYROID CARCINOMA: NATIONAL THYROID CANCER TREATMENT COOPERATIVE STUDY GROUP REGISTRY ANALYSIS 1987-2012 <b>Aubrey Carhill, D.R. Litofsky, K. Ain, J. Brierley, D.S. Cooper, H. Fein, B. Haugen, J. Jonklaas, P. Ladenson, J. Magner, D. Ross, M. Skarulis, D. Steward, M. Xing, H. Maxon, S.I. Sherman</b></p>	<p>Oral Abstract 5, <i>Thyroid Cancer, Basic</i> KRASG12D MEDIATED ONCOGENIC TRANSFORMATION OF THYROID FOLLICULAR CELLS REQUIRES LONG-TERM TSH STIMULATION AND IS REGULATED BY SPY1 <b>Yufei Shi, M. Zou, E. Baitei, R. Al-Rijjal, R. Parhar, F. Al-Mohanna, S. Kimura, C. Pritchard, A. Alzahrani, A. Assiri, B. Meyer</b></p>
<p>Oral Abstract 12, <i>Autoimmunity, Clinical</i> INDUCTION OF PAINLESS THYROIDITIS IN PATIENTS RECEIVING PROGRAMMED DEATH 1 RECEPTOR IMMUNOTHERAPY FOR METASTATIC MALIGNANCIES <b>S. Orlov, F. Salari, L. Kashat, J. Alfaifi, Paul G. Walfish</b></p>	<p>Oral Abstract 6, <i>Thyroid Cancer, Basic</i> SEX HORMONES REGULATE THYROID CANCER INITIATION AND PROGRESSION BY MODIFYING TUMOR SUPPRESSOR GENE EXPRESSION AND TUMOR IMMUNITY <b>Lisa J. Zhang, Y. Xiong, N. Nilubol, M. He, S. Bommareddi, X. Zhu, L. Jia, Z. Xiao, J. Park, X. Xu, D. Patel, M.C. Willingham, S. Cheng, E. Kebebew</b></p>
<p>Oral Abstract 13, <i>Thyroid Cancer, Clinical</i> PROGNOSTIC AND PREDICTIVE FACTORS CORRELATED WITH TREATMENT OUTCOMES FOR RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER (RAI-RDTC) PATIENTS RECEIVING SORAFENIB OR PLACEBO ON THE PHASE III DECISION TRIAL <b>Martin Schlumberger, R. Elisei, F. Pacini, B. Jarzab, L. Giannetta, L. Bastholt, C. De la Fouchardiere, R. Paschke, F. Worden, Y. Shong, J. Smit, C. Kappeler, I. Molnar, M.S. Brose</b></p>	<p>Oral Abstract 7, <i>Thyroid Cancer, Basic</i> <b>COOPERATIVE</b> ACTIVATION OF <i>TERT</i> BY <i>BRAF</i> V600E AND <i>TERT</i> PROMOTER MUTATIONS: A NOVEL MOLECULAR MECHANISM IN THYROID TUMORIGENESIS <b>Rengyun Liu, M. Xing</b></p>
<p>Oral Abstract 14, <i>Thyroid Cancer, Clinical</i> IS PREOPERATIVE VITAMIN D DEFICIENCY A RISK FACTOR FOR POSTOPERATIVE SYMPTOMATIC HYPOCALCEMIA IN THYROID CANCER PATIENTS UNDERGOING TOTAL THYROIDECTOMY PLUS CENTRAL COMPARTMENT NECK DISSECTION? <b>W. Kim, J. Jeong, S. Jung, C. Lee, S. Kang, J. Lee, J. Jung, Kee Hyun Nam, W. Chung, C. Park</b></p>	<p>Oral Abstract 8, <i>Iodine Uptake &amp; Metabolism, Basic</i> EFFECTIVE <sup>131</sup>I THERAPY OF METASTATIC COLON CANCER AFTER MESENCHYMAL STEM CELL-MEDIATED TUMOR STROMA TARGETING OF THE SODIUM IODIDE SYMPORTER <b>K. Knoop, N. Schwenk, K.A. Schmohl, A. Mueller, C. Zach, C. Cyran, J. Carlsen, G. Böning, P. Bartenstein, B. Göke, E. Wagner, P.J. Nelson, Christine Spitzweg</b></p>
<p>Oral Abstract 15, <i>Thyroid Cancer, Clinical</i> IMPACT OF RADIOACTIVE IODINE ON SURVIVAL IN PAPILLARY THYROID CARCINOMA <b>D. Boone, Paritosh Suman, R. Prinz, T. Moo-Young, D.J. Winchester</b></p>	<p>Oral Abstract 9, <i>Thyroid Cancer, Basic</i> <i>BRAF</i><sup>V600E</sup>-DRIVEN MURINE ANAPLASTIC THYROID CANCERS RECUR AFTER WITHDRAWAL OF THE ONCOPROTEIN, AND REACTIVATE MAPK SIGNALING IN A <i>BRAF</i><sup>V600E</sup>-INDEPENDENT MANNER <b>Jeffrey A. Knauft, K. Chen, R.A. Ghossein, J. Fagin</b></p>
<p>Oral Abstract 16, <i>Thyroid Cancer, Clinical</i> POSTOPERATIVE NOMOGRAM FOR PREDICTING CANCER-SPECIFIC MORTALITY IN MEDULLARY THYROID CANCER <b>A.S. Ho, L. Wang, F.L. Palmer, C. Yu, A. Tosef, S.G. Patel, M.W. Kattan, M.R. Tuttle, Ian Ganly</b></p>	

**Poster Review Session and Break in the Exhibit Hall 3:20 PM – 3:50 PM**

**Simultaneous Symposia 3:50 PM – 5:05 PM**

<b>Clinical: Voice Symposium, Surgically Related</b> <i>Chair: Amy Chen</i>	<b>Basic: Thyroid Cell Biology</b> <i>(Dedicated to the Memory of Paul Kim)</i> <i>Chair: Fredric Wondisford</i>
<p>Getting the Most Out of the New Guidelines (ATA and AAO-HNSF) <b>David Terris</b> Novel Ways to Image Vocal Cord Function <b>Denise Carneiro-Pla</b> State of the Science: Use of Intraoperative Nerve Monitoring and Prediction of Long Term Outcomes <b>Quan-Yang Duh</b></p>	<p>To Be or Not to Be: How Thyroglobulin Mutations and Folding Affect Thyroid Survival and Growth <b>Peter Arvan</b> Unraveling the Mysteries of the Sodium Iodide Symporter (NIS) <b>Nancy Carrasco</b> Physiology and Pathophysiology of the Dual Oxidases DUOX1 and 2 <b>Xavier De Deken</b></p>

**Symposium: Intersecting Autoimmunity, Immuno-Modulators and Thyroid Dysfunction – Updates and Emerging Themes 5:10 PM – 6:25 PM**

*Chair: Terry Davies*

Thyroid Dysfunction as a Component of Autoimmune Polyendocrinopathy Syndrome **George Kahaly**  
Thyroid Dysfunction Associated with Other Autoimmune Diseases **Kristien Boelaert**  
Thyroid Dysfunction Associated with Immune Modulating Therapies **Mabel Ryder**

**ATA Annual Business Meeting 6:30 PM – 7:30 PM**

*(for ATA Active and senior members only)*

**FREE EVENING**

<b>84<sup>th</sup> Annual Meeting of the ATA</b> Friday, October 31, 2014	
Registration Open 6:30 AM – 5:30 PM	
<b>Early Riser Symposium: Radioactive Iodine Remnant Ablation: Selecting the Proper Patients, Preparation Method and Administered Activity</b> 6:45 AM – 8:00 AM <i>Chair: Laura Boucai</i>	
Risk Stratification in Differentiated Thyroid Cancer Fabian Pitoia Guidelines for Patient Selection for Radioactive Iodine Ablation Leonard Wartofsky ESTIMBL and Hi-Lo: What Did We Learn, What Is Next? Ujjal Mallick	
<b>Van Meter Lecture</b> 8:10 AM – 8:55 AM <i>Introduction: To be announced onsite</i> <i>Speaker: To be announced onsite</i>	
<b>Simultaneous Symposia</b> 9:00 AM – 10:15 AM	
<p><b>Clinical: ICCIDD Iodine Deficiency Symposium</b> <i>(Dedicated to the Memory of Gerard “Gerry” Burrow)</i> <i>Chairs: Elizabeth Pearce and Angela Leung</i></p> <p>Iodine in Veterinary Populations Charlene Edinboro David Marine and the Elimination of Endemic Goiter in the United States J. Woody Sistrunk</p>	<p><b>Basic: Thyroid Hormone Regulation of Growth and Development</b> <i>Chair: Anthony Hollenberg</i></p> <p>Thyroid Hormone and the Auditory System Douglas Forrest The Role of Thyroid Hormone on Cerebral Cortex Development Beatriz Morte Molina Roles of Thyroid Hormone Receptors in the Regulation of Thyroid Growth Sheue-yann Cheng</p>
Exhibit Hall Open 10:00 AM – 4:30 PM Poster Review Session and Break in the Exhibit Hall 10:15 AM – 11:15 AM	
<b>Simultaneous Symposia</b> 11:15 AM – 12:30 PM	
<p><b>Arthur Bauman Clinical Symposium: Behind the Scenes - Difficult Decisions, Controversies and Logic in Developing ATA Guidelines</b> <i>Chair: Glenn Braunstein</i></p> <p>Thyroid Nodules and Differentiated Thyroid Cancer Guidelines Bryan Haugen Medullary Thyroid Cancer Guidelines Samuel Wells Hypothyroidism Guidelines: To T3 or Not to T3 and Other Questions About the Treatment of Hypothyroidism Jacqueline Jonklaas</p>	<p><b>Basic: The Journey of Thyroid Hormone into the Cell Nucleus</b> <i>Chair: Sheue-yann Cheng</i></p> <p>Cell Membrane Transporter Heike Heuer Cellular Deiodinase Regulation Elizabeth McAninch Role of Transthyretin in Placental Thyroid Hormone Transport Kerry Richard</p>
<b>Lunch and Poster Review on Your Own</b> 12:30 PM – 1:25 PM	
<b>ATA Women in Thyroidology Networking Meeting</b> 12:30 PM – 1:25 PM	
<b>ATA Expo Theater with Veracyte, Inc</b> 12:30 PM – 1:25 PM The Scientific Story Behind Afirma Thyroid FNA Analysis <i>(Open to all attendees; space limited – first come, first served)</i> Speakers: Giulia C. Kennedy and Richard T. Kloos	
<b>Lewis E. Braverman Award Lecture: A Tale of Two Iodines: And the Braverman/Wartofsky Intersection</b> 1:30 PM–2:15 PM <i>Introduction: Elizabeth Pearce</i> <i>Speaker: Leonard Wartofsky</i>	
<b>Meet the Professor Workshops (5 total)</b> 2:20 PM – 3:20 PM	
<p style="text-align: center;">Clinical</p> <ul style="list-style-type: none"> <li>• Serum Thyroglobulin in the Management of Differentiated Thyroid Cancer: An Update in 2014 Carole Spencer and Robert Smallridge</li> <li>• Evaluation of Thyroid Nodules: What is the Role of Molecular Markers? Julie Ann Sosa and Anna Sawka</li> <li>• Evaluation and Management of Thyroid Nodules and Thyroid Cancer in the Pediatric Population Stephen Huang</li> </ul>	<p style="text-align: center;">Translational/Basic</p> <ul style="list-style-type: none"> <li>• ATA Basic Research Guidelines: How to Manipulate Thyroid Status in Animal Models Tania Ortiga-Carvalho</li> <li>• Role of TRs in Cell Differentiation and Senescence Ana Aranda</li> </ul>
<b>Clark T. Sawin Historical Vignette: Theodor Kocher (1841-1917) – A Lasting Legacy</b> 3:25 PM – 3:50 PM <i>Introduction: Jeffrey Garber</i> <i>Speaker: Peter Kopp</i>	
<b>Poster Review and Break</b> 3:50 PM – 4:20 PM	

**84th Annual Meeting of the ATA**  
Friday, October 31, 2014 (continued)

**Research Grants Symposium 4:20 PM – 5:05 PM**  
Chair: *Mingzhao Xing*

An Investigation of the LDLR-Independent Serum Lipid Modulation by Thyroid Hormone Stephen Ayers  
Type 3 Deiodinase in Dilated Heart Failure Ari J. Wassner  
Sorafenib and Quinacrine as Potential Combination for Anaplastic Thyroid Carcinoma Niklas Finnberg

**Oral Abstract Sessions 5:10 PM– 6:40 PM**

Clinical (6 total)  
Chairs: *Kenneth Ain and Brian Kim*

Oral Abstract 121, *Thyroid Cancer, Translational*  
TUMOR SUPPRESSOR MIR-30A-5P INHIBITS LOX  
EXPRESSION AND CANCER PROGRESSION IN  
THYROID CANCER **Myriam Boufraqueh**, *N. nilubol, L.  
Zhang, S. gara, S. Sadowski, A. Mehta, M. He, S. davis, J.  
Dreiling, J.A. Copland, R.C. Smallridge, M. Quezado, E.  
Kebebew*

Oral Abstract 122, *Thyroid Cancer, Translational*  
DETECTION OF CIRCULATING BRAFV600E IN  
PATIENTS WITH PAPILLARY THYROID CARCINOMA  
**Carrie C. Lubitz**, *S. Parangi, M. Bernasconi, A.P. Schalck,  
D.T. Frederick, H. Suh, S.E. Donovan, L. Wirth, R.J. Sullivan,  
D.J. Panka*

Oral Abstract 123, *Thyroid Cancer, Clinical*  
HIGHLY ACCURATE DIAGNOSIS OF CANCER IN  
THYROID NODULES WITH FOLLICULAR  
NEOPLASM/SUSPICIOUS FOR A FOLLICULAR  
NEOPLASM CYTOLOGY BY THYROSEQ V2 NEXT  
GENERATION SEQUENCING ASSAY **Yuri Nikiforov**,  
*S.E. Carty, S.I. Chiosea, C. Coyne, U. Duvvuri, R.L. Ferris, S.  
Hodak, S.O. LeBeau, N. Oho, R.R. Seethala, M.E. Tublin, L.  
Yip, M. Nikiforova*

Oral Abstract 124, *Thyroid Cancer, Translational*  
MUTATIONAL ANALYSIS OF KINOME IN  
DIFFERENTIATED THYROID CANCER **Tae Hyuk Kim**,  
*J. Park, D. Park, K. Lee, J. Moon, K. Kim, K. Yi, D. Park, Y.  
Park*

Oral Abstract 125, *Thyroid Cancer, Clinical*  
DEVELOPMENT OF A CLINICAL TARGETED NEXT-  
GENERATION SEQUENCING TEST FOR  
INDETERMINATE THYROID NODULES **Shih-Min  
Cheng**, *D. Lew, C. Barlan, F.M. Hantash, J.J. Catanese, A.  
Grupe, D. Ross, R.E. Reitz, F.M. Waldman*

Oral Abstract 126, *Thyroid Cancer, Translational*  
IDENTIFICATION OF IODINE METABOLISM-  
ASSOCIATED LARGE NON-CODING RNA (LINCRNA)  
DIFFERENTIALLY EXPRESSED IN BRAFV600E-  
POSITIVE PAPILLARY THYROID CANCER VERSUS  
NORMAL THYROID TISSUE *M. Duquette, A. Fischer, E.  
Puxeddu, J. Lawler, P. Pandolfi, Carmelo Nucera*

Basic/Translational (6 total)  
Chairs: *Terry Davies and Theo Visser*

Oral Abstract 115, *Thyroid Cancer, Basic*  
MICRORNA-339-5P MODULATES NA<sup>+</sup>/I<sup>-</sup> SYMPORTER-  
MEDIATED RADIOIODIDE UPTAKE **Aparna  
Lakshmanan**, *A. Wojcicka, M. Kotlarek, K. Jazdzewski, S.M.  
Jhiang*

Oral Abstract 116, *Thyroid Cancer, Basic*  
TARGETED DELIVERY OF A NOVEL HISTONE  
DEACETYLASE INHIBITOR, AB3, USING  
UNIMOLECULAR MICELLES TO IMPROVE  
ANTITUMOR EFFECT IN MEDULLARY THYROID  
CANCER **Renata Jaskula-Sztul**, *G. Chen, A.D. Harrison, A.  
Dammalapati, R. Nair, G. Winston-McPherson, C.  
Scheinebeck, W. Tang, S. Gong, H. Chen*

Oral Abstract 117, *Autoimmunity, Basic*  
STANDARDIZATION OF A FDA-CLEARED BIOASSAY  
CONVERTS THYROID-STIMULATING ANTIBODY  
LEVELS INTO INTERNATIONAL UNITS ENABLING  
COMPARISON AMONG LABORATORIES **Tanja Diana**,  
*M. Kanitz, M. Lehmann, J. Franken, G.J. Kahaly*

Oral Abstract 118, *Thyroid Hormone Action, Basic*  
THYROID HORMONE INTERACTS WITH ALPHA2C  
ADRENERGIC RECEPTOR SIGNALING TO REGULATE  
THE EPIPHYSIAL GROWTH PLATE MORPHOLOGY  
AND BONE GROWTH **Manuela M. Rodrigues**, *M.V. Silva,  
P.C. Brum, C.H. Gouveia*

Oral Abstract 119, *Disorders of Thyroid Function, Basic*  
TSH RECEPTOR ENDOCYTIC CARGO DETERMINES  
THYROCYTE CELL FATE **Syed A. Morshed**, *R. Ma, R.  
Latif, T.F. Davies*

Oral Abstract 120, *Thyroid Hormone Metabolism &  
Regulation, Basic*  
PHARMACOLOGICAL ACTIVATION OF THYROID  
HORMONE RECEPTORS ELICITS A FUNCTIONAL  
CONVERSION OF WHITE TO BROWN FAT **Kevin  
Phillips**, *J.Z. Lin, A.J. Martagón, S.L. Cimini, D.D. Gonzalez,  
S.M. Hartig, A. Biter, N. Zhang, J.D. Baxter, P. Webb, J.  
Gustafsson*

**ATA Annual Banquet 7:30 PM – 11:00 PM (Admission with ticket only)**

**84<sup>th</sup> Annual Meeting of the ATA**

Saturday, November 1, 2014

Registration Open 6:30 AM – 5:30 PM

**Early Riser Symposium: Management of Advanced Radioactive Iodine Refractory Thyroid Cancer**

6:45 AM – 8:00 AM

Chair: *Maria E. Cabanillas*

What is the Definition of Radioactive Iodine Refractory? *Stephanie Lee*  
Opportunities for the Use of Locoregional/Directed Therapies in Radioiodine-Refractory Thyroid Cancers *Keith Bible*  
Initiation of Systemic Therapy: Which Agents and When? *Rossella Elisei*

**Plenary Lecture: Excess Thyroid Hormone and Thyrotroph Cell Death 8:10 AM – 8:55 AM**

Introduction: *Yun-Bo Shi*

Speaker: *Rolf Karlstrom*

**Short Call Oral Abstracts (6 total) 9:00 AM – 10:30 AM**

Chairs: *Elizabeth Pearce and Antonio Bianco*

Short Call Oral 1, *Thyroid Cancer, Translational*  
TERT PROMOTER AND BRAF MUTATIONS COOPERATIVELY PROMOTE PAPILLARY THYROID CANCER-RELATED MORTALITY **Mingzhao Xing**, *R. Liu, J. Bishop*

Short Call Oral 2, *Thyroid Cancer, Basic*  
NF2/MERLIN IS A NOVEL THYROID TUMOR SUPPRESSOR GENE WHOSE LOSS PROMOTES ONCOGENIC RAS-INDUCED THYROID CANCERS VIA YAP-DEPENDENT TRANSACTIVATION OF MUTANT RAS AND SENSITIZES THEM TO MEK INHIBITION **Maria E. Garcia-Rendueles**, *J. Ricarte Filho, B.R. Untch, J.A. Knauf, V. Smith, E. Lundsmith, B. Taylor, G. Oler, S.C. Jhanwar, A. Viale, F. Giancotti, Y. Fang, A. Heguy, K.H. Huberman, M. Ryder, R.A. Ghossein, J. Fagin*

Short Call Oral 3, *Thyroid Cancer, Translational*  
TARGETING OF ONCOGENIC HRAS IN MURINE AGGRESSIVE THYROID CANCERS WITH MEK AND FARNESYLTRANSFERASE INHIBITION **Brian R. Untch**, *J.A. Knauf, M.E. Garcia-Rendueles, R.A. Ghossein, A.L. Ho, J. Fagin*

Short Call Oral 4, *Autoimmunity, Translational*  
MUTATIONS IN NOX3 AS GENETIC CAUSE OF FAMILIAL AGRANULOCYTOSIS DURING THYROSTATIC TREATMENT OF GRAVES' DISEASE **Theo S. Plantinga**, *P. Arts, G.H. Knarren, A.H. Mulder, I.M. Wakelkamp, A. Hoischen, M. Netea, J. Smit, R.T. Netea-Maier*

Short Call Oral 5, *Thyroid Cancer, Translational*  
IDENTIFICATION OF NOVEL GENE FUSIONS BY TARGETED NEXT-GEN SEQUENCING IN THYROID FNA SAMPLES **Marina Nikiforova**, *S. Zhong, A. Wald, L. Kelly, Y. Nikiforov*

Short Call Oral 6, *Thyroid Hormone Action, Basic*  
A ROLE FOR THYROID HORMONE ACTIVATION IN THE TREATMENT OF X-LINKED ADRENOLEUKODYSTROPHY (X-ALD) **Meredith D. Hartley**, *T. Banerji, T.S. Scanlan*

Exhibit Hall Open 9:30 AM – 1:30 PM

**Poster Review Session and Break in the Exhibit Hall 10:30 AM – 11:30 AM**

**Meet the Professor Workshops (5 total) 11:30 AM – 12:30 PM**

**Clinical**

- Radioactive Iodine Therapy in Benign Goiter *Laszlo Hegedus*
- Correlating Outcomes with the Histological Description of Follicular Cell Derived Thyroid Cancers: What Is The Clinical Relevance? *Ronald Ghossein and Victor Bernet*
- Should BRAF Status Influence Initial Management Decisions in Differentiated Thyroid Cancer? *Sally Carty and Kopal Patel*

**Basic/Translational**

- What is New for Thyroid Hormone Transporters *Theo Visser*
- ATA Basic Science Handbook *Antonio Bianco*

**Lunch and Poster Review on Your Own 12:30 PM – 1:25 PM**

**ATA Expo Theater with MedImmune, Specialty Care Division of AstraZeneca 12:30 PM – 1:25 PM**

Clinical Considerations in Advanced Medullary Thyroid Cancer (MTC) Patient Management  
(Only U.S. health care professionals are permitted to attend this program; space limited – first come, first served; lunch served)  
Speaker: *Kate Newbold*

**Exhibit Hall Closes 1:30 PM**

**84th Annual Meeting of the ATA**

*Saturday, November 1, 2014 (continued)*

**Paul Starr Award Lecture: What Can a Clinician Contribute? 1:30 PM – 2:15 PM**

*Introduction: Gregory Randolph*

*Speaker: Gilbert Daniels*

**Oral Abstract Sessions 2:20 PM – 3:20 PM**

Clinical (4 total) <i>Chairs: Giuseppe Barbesino and Rebecca Leboeuf</i>	Basic/Translational (4 total) <i>Chairs: Sandra McLachlan and Yaron Tomer</i>
<p>Oral Abstract 219, <i>Thyroid &amp; Development, Clinical</i> PREGNANCY OUTCOMES OF EXPOSURE TO METHIMAZOLE (POEM) STUDY: AN INTERIM REPORT <b>Naoko Arata, A. Murashima, S. Ito, Y. Ohashi, H. Onose, K. Kosaki, R. Kosaki, J. Tajiri, N. Hamada, Y. Hidaka, S. Fukata, N. Momotani, S. Kubota, H. Yoshikawa</b></p> <p>Oral Abstract 220, <i>Thyroid &amp; Development, Translational</i> IS SEVERITY OF HYPOTHYROIDISM AT BIRTH ASSOCIATED WITH ABNORMAL CORTICAL DEVELOPMENT IN CHILDREN WITH CONGENITAL HYPOTHYROIDISM? <b>Joanne F. Rovet, H. Clairman, J. Lischinsky, J. Skocic</b></p> <p>Oral Abstract 221, <i>Disorders of Thyroid Function, Clinical</i> MYXEDEMA COMA DIAGNOSIS AND TREATMENT: A CASE SERIES OF 45 PATIENTS FROM 2004-2014 TREATED WITH 500MCG OF IV L-THYROXINE <b>K.C. Wu, Caroline T. Nguyen, J.S. LoPresti, D.A. Cohen</b></p> <p>Oral Abstract 222, <i>Disorders of Thyroid Function, Clinical</i> HYPERTHYROIDISM INCIDENCE VARIATION IN AND AROUND FIRST AND SUBSEQUENT PREGNANCIES: A DANISH POPULATION-BASED STUDY <b>S.L. Andersen, A. Carlé, J. Olsen, Peter Laurberg</b></p>	<p>Oral Abstract 215, <i>Thyroid Hormone Action, Basic</i> ROLES OF THYROID HORMONE-TARGET GENE HISTONE H3K79 METHYLTRANSFERASE DOT1L DURING EMBRYOGENESIS AND ADULT STEM CELL DEVELOPMENT <b>Yun-Bo Shi</b></p> <p>Oral Abstract 216, <i>Thyroid &amp; Development, Basic</i> THYROID HORMONE DRIVING LARVAL CELLS MAD: THE ROLE OF C-MYC GENE FAMILY IN THYROID HORMONE-DEPENDENT INTESTINAL STEM CELL DEVELOPMENT <b>Thomas C. Miller, M. Okada, Y. Shi</b></p> <p>Oral Abstract 217, <i>Thyroid &amp; Development, Basic</i> THE HISTONE METHYLTRANSFERASE PRMT1 REGULATES ADULT INTESTINAL STEM CELL DEVELOPMENT IN MICE <b>Julia Rodiger, Y. Zhang, Y. Shi</b></p> <p>Oral Abstract 218, <i>Disorders of Thyroid Function, Basic</i> XB130 DEFICIENCY RESULTS IN MOUSE THYROID HORMONE SYNTHESIS DISORDER <b>Hiroki Shimizu, Y. Wang, H. Toba, H. Cho, X. Bai, S.L. Asa, X. Liao, S. Refetoff, M. Liu</b></p>

**Simultaneous Symposia 3:25 PM – 4:40 PM**

<b>Clinical: Evolution of Imaging Modalities in Thyroid Cancer</b> <i>Chairs: Anni Morsing and Ron Koenig</i>	<b>Basic: Thyroid Hormone Receptors: Insights from Disease Models</b> <i>Chair: Graham Williams</i>
<p>Update on Sonography in Thyroid Cancer Surveillance and Novel Therapeutic Strategies for Nodal Metastases <b>Robert Lee</b></p> <p>FDG and Beyond: Evolution of Positron-Emission Tomography Tracers in Advanced Thyroid Cancers <b>Trond Velde Bogsrud</b></p> <p>Personalized Approaches in Thyroid Cancer Imaging - The Future <b>Anni Morsing</b></p>	<p>Prereceptor Defects in Humans <b>Alexandra Dumitrescu</b></p> <p>THRA Human Mutations <b>Carla Moran</b></p> <p>THRB Human Mutations <b>Samuel Refetoff</b></p>

Break 4:40 PM – 4:55 PM

**Symposium: More Everyday Ethical Dilemmas for Thyroid Practitioners 2014 4:55 PM – 6:10 PM**

*Moderator: Cheryl Fassler*

Thyroidology and the Public Trust **Loren Wissner Greene**  
Informed Consent for Non-Standard or Innovative Therapies in Thyroidology **M. Sara Rosenthal**  
Mandatory Return of Results for the RET Mutations: New Ethical Dilemmas for the Thyroid World **Peter Angelos**

**FREE EVENING**

**84<sup>th</sup> Annual Meeting of the ATA**  
Sunday, November 2, 2014

Registration Open 8:00 AM – 11:30 AM

**Symposium: Contemporary Evaluation and Management of Thyroid Nodules**

8:00 AM – 9:15 AM

*Chair: Melanie Goldfarb*

Using Ultrasound to Risk Stratify Thyroid Nodules and Guide Selection for FNA Andrew Gianoukakis  
Rationale Follow-up of Cytologically Benign Thyroid Nodules Ralf Paschke  
Minimally Invasive Therapy for Benign and Malignant Nodules Enrico Papini

**Thyroid Cancer Tumor Board 9:30 AM – 11:00 AM**

*Moderator: Steven I. Sherman*

Endocrinology: Douglas Ball  
Surgery: Ralph Tufano  
Nuclear Medicine: Daniel A. Pryma  
Radiation Oncology: James Brierley  
Oncology: Marcia Brose  
Pathology: Yuri Nikiforov

**84<sup>th</sup> Annual Meeting Ends 11:00 AM**



**American Thyroid Association**

6066 Leesburg Pike, Suite 550  
Falls Church, VA 22041

Phone: 703-998-8890 Fax: 703-998-8893  
Email: [thyroid@thyroid.org](mailto:thyroid@thyroid.org) Website: [www.thyroid.org](http://www.thyroid.org)